Novo Nordisk Teams With Aspect Biosystems On Diabetes Cell Therapy
Executive Summary
Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.